Adaptimmune stock plunges after announcing Nasdaq delisting plans
Director Daniel C. Snow acquired 3,333 shares of CPS Technologies CORP/DE/ (NASDAQ:CPSH) common stock on October 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $3.0, totaling $9999. The stock, which has seen a remarkable 142% return over the past year, currently trades at $3.93. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.34. Following the transaction, Snow directly owns 11,941 shares of the company, representing a stake in this $57.45 million market cap enterprise. According to InvestingPro’s Fair Value model, the stock appears slightly overvalued at current levels. For deeper insights into insider trading patterns and 8 additional key ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, CPS Technologies Corp. announced the completion of a public stock offering, raising approximately $10.35 million in gross proceeds. The company sold 3,000,000 shares of common stock at $3.00 per share, with an additional 450,000 shares sold through an over-allotment option. The offering was managed by Roth Capital Partners, which served as the sole book-running manager. Earlier, CPS Technologies had announced the pricing of the offering, expected to generate about $9 million before underwriting costs and expenses. The net proceeds are intended for general corporate purposes such as working capital and capital expenditures. Additionally, CPS Technologies has been awarded a $125,000 Phase I SBIR contract by the U.S. Department of Energy. This contract will support research on high-performance impact limiters for nuclear safety, with the project set to continue until April 2026. These developments reflect the company’s ongoing strategic initiatives and expansion efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.